09.07.20
ProBiotix Health, (a subsidiary of OptiBiotix Health PLC), which specializes in microbiome-modulating compounds, has launched a tri-layer tablet supplement, CholBiome BP, which combines four science-backed, natural ingredients to aid hypertension and cardiovascular health.
According to the World Health Organization (WHO), an estimated 1.13 billion people worldwide have hypertension, a major cause of premature death. Two thirds of those affected live in low- and middle-income countries. One in four men and one in five women have experienced hypertension, and fewer than one in five individuals with hypertension have been able to keep it under control.
To help tackle the global health issue, ProBiotix has adopted a multi-targeted mechanism approach to improve cardiovascular health. CholBiomeBP utilizes specialized tri-layer tablet technology to combine four synergistic ingredients—which the company said have previously been incompatible—and slowly releases them into the human body. This multi-tiered approach increases the supplement’s stability and survivability throughout the digestive system, and boosts its effectiveness, according to the company.
“We are thrilled to launch CholBiomeBP as part of the CholBiome brand portfolio,” said Mikkel Hvid-Hansen, commercial director at ProBiotix. “As health and wellness becomes front of mind for many, CholBiomeBP is a natural food supplement containing our patented probiotic strain LPLDL, Thiamine (vitamin B1), which contributes to the normal function of the heart, the semi-essential amino acid L-Arginine and the micronutrient Coenzyme Q10. By combining all four ingredients together in a unique way, CholBiomeBP helps to support normal cardiac function, as recognized by EFSA (European Food Safety Authority).”
In an independent, 12-week clinical human study that included 40 adults with high blood pressure, CholBiomeBP demonstrated its efficacy with a decrease in diastolic blood pressure and a reduction in systolic blood pressure. In addition, the supplement also resulted in a drop in bad LDL cholesterol and a decrease in total cholesterol. This means the GMO and allergen free product is an effective way to aid hypertension in adults and improve overall cardiovascular health.
Steven Riley, director of marketing and consumer sales at OptiBiotix, said: “We’re pleased to announce that CholBiomeBP will be joining the OptiBiotix Online store and will be complementing our growing science-backed cardiovascular health range. The blood pressure reducing supplement is a key part of our commercial growth and is an exciting step forward to support consumers on their journey towards a healthier lifestyle.
“As a global company with headquarters in the U.K., we want to raise awareness of how important it is for consumers to get their blood pressure checked. We encourage those who are worried about their blood pressure to measure it at home with an accurate reader as per guidance from the British Heart Foundation.”
According to the World Health Organization (WHO), an estimated 1.13 billion people worldwide have hypertension, a major cause of premature death. Two thirds of those affected live in low- and middle-income countries. One in four men and one in five women have experienced hypertension, and fewer than one in five individuals with hypertension have been able to keep it under control.
To help tackle the global health issue, ProBiotix has adopted a multi-targeted mechanism approach to improve cardiovascular health. CholBiomeBP utilizes specialized tri-layer tablet technology to combine four synergistic ingredients—which the company said have previously been incompatible—and slowly releases them into the human body. This multi-tiered approach increases the supplement’s stability and survivability throughout the digestive system, and boosts its effectiveness, according to the company.
“We are thrilled to launch CholBiomeBP as part of the CholBiome brand portfolio,” said Mikkel Hvid-Hansen, commercial director at ProBiotix. “As health and wellness becomes front of mind for many, CholBiomeBP is a natural food supplement containing our patented probiotic strain LPLDL, Thiamine (vitamin B1), which contributes to the normal function of the heart, the semi-essential amino acid L-Arginine and the micronutrient Coenzyme Q10. By combining all four ingredients together in a unique way, CholBiomeBP helps to support normal cardiac function, as recognized by EFSA (European Food Safety Authority).”
In an independent, 12-week clinical human study that included 40 adults with high blood pressure, CholBiomeBP demonstrated its efficacy with a decrease in diastolic blood pressure and a reduction in systolic blood pressure. In addition, the supplement also resulted in a drop in bad LDL cholesterol and a decrease in total cholesterol. This means the GMO and allergen free product is an effective way to aid hypertension in adults and improve overall cardiovascular health.
Steven Riley, director of marketing and consumer sales at OptiBiotix, said: “We’re pleased to announce that CholBiomeBP will be joining the OptiBiotix Online store and will be complementing our growing science-backed cardiovascular health range. The blood pressure reducing supplement is a key part of our commercial growth and is an exciting step forward to support consumers on their journey towards a healthier lifestyle.
“As a global company with headquarters in the U.K., we want to raise awareness of how important it is for consumers to get their blood pressure checked. We encourage those who are worried about their blood pressure to measure it at home with an accurate reader as per guidance from the British Heart Foundation.”
